These data indicate that the p53–Nedd4–Runx2 axis is an effective regulator of bone formation and highlight the potential of beraprost as a therapeutic drug for postmenopausal osteoporosis. The gene discussed is RUNX2; the disease is postmenopausal osteoporosis.